Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Astria Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Astria Therapeutics, Inc.

ATXS

Astria Therapeutics, Inc.

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc. is a biopharmaceutical company developing novel monoclonal antibody therapies for allergic and immunological diseases. Its lead candidates include navenibart, a plasma kallikrein inhibitor for hereditary angioedema (HAE), and STAR-0310, an OX40 antagonist for atopic dermatitis (AD). Astria focuses on long-acting, patient-friendly treatments targeting unmet medical needs, leveraging validated mechanisms and third-party manufacturing to serve global specialty markets.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Astria Therapeutics, Inc.

1
1
Astria Therapeutics, Inc. Astria Therapeutics Reports Q3 2025 Financial Results with Increased Collaboration Revenue and Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
Astria Therapeutics, Inc. Astria Therapeutics Reports $66.8 Million Net Loss for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
Astria Therapeutics, Inc. Astria Therapeutics Reports $33.7 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
Astria Therapeutics, Inc. Astria Therapeutics Reports $94.26 Million Net Loss for 2024, Driven by Increased R&D Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
Astria Therapeutics, Inc. Astria Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments